Novalix is a premier contract research organization dedicated to improving the critical early stages of drug discovery by combining exceptional scientific talent and exclusive technology with a comprehensive portfolio of world-class chemistry, biophysics and pharmacology capabilities. Novalix works collaboratively with its clients to meet the most complex scientific challenges, and its innovative partnerships with leading instrument makers and academic institutions help it continually expand the possibilities of human health.

From early discovery to candidate selection, Novalix tailors every project around clients’ needs and goals. Every engagement is driven by experienced scientists using exceptional technology to increase the odds of success at each stage.

Comprehensive capabilities are organized into five centers of excellence: Chemistry, Biophysics, Pharmacology and DMPK, Drug Discovery, and Cosmetics.
A wide range of areas is covered, including medicinal chemistry, cheminformatics, synthetic chemistry, process chemistry and scale-up, biophysics (NMR, MS, SPR), protein production with a focus on GPCRs, and structural biology techniques such as cryo-EM, protein X-ray crystallography, and NMR. Novalix also excels in in vitro and in vivo pharmacology, translational science, biobanking, histology, ADME-DMPK, and pre-formulation.

Scientific expertise includes diverse modalities, such as small molecules, biologics (mAbs, ADCs), and PROTACs. The company focuses on various therapeutic areas, namely oncology, immuno-inflammation, infectious diseases, fibrosis, kidney diseases, osteoarthritis, and metabolic disorders.

State-of-the-art facilities are located in France and Tunisia, with business representative offices in the United States and Japan, ensuring a global presence and reach.